C1 inhibitor: Just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor

Expert Opinion on Biological Therapy

Volumn 8, Issue 8, 2008, Pages 1225-1240

  Wouters, Diana ^a   Wagenaar Bos, Ineke ^a   Van Ham, Marieke ^a   Zeerleder, Sacha ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

C1 inhibitor; Cardiopulmonary bypass surgery; Complement system; Contact system; Hereditary angioedema; Myocardial infarction; Sepsis; ST elevation myocardial infarction

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; BERINERT P; CETOR; CINRYZE; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DX 88; ECALLANTIDE; HYPERTENSIVE AGENT; ICATIBANT; KALLIKREIN INHIBITOR; RHUCIN;

ABSENCE OF SIDE EFFECTS; ANGIONEUROTIC EDEMA; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; COMPLEMENT SYSTEM; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTESTINE ISCHEMIA; LIVER ISCHEMIA; LIVER TOXICITY; NONHUMAN; REPERFUSION INJURY; REVIEW; SEPSIS; SEPTIC SHOCK; VIRILIZATION;

ANGIOEDEMA, HEREDITARY; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; CORONARY ARTERY BYPASS; HUMANS; MYOCARDIAL INFARCTION; SERINE PROTEINASE INHIBITORS;

EID: 48049096410     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.8.1225     Document Type: Review

References (176)

1. Mason DT, Melmon KL. Effets of bradykinin on fore-arm venous tone and vascular resistance in man. Circ Res 1965;17:106-13
2. Vogt W. Anaphylatoxins: possible roles in disease. Complement 1986;3:177-80
3. Sim RB, Reboul A, Arlaud GJ, et al. Interaction of 1125-labelled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBS Lett 1979;97:111-5
4. Van den Graaf F, Koedam JA, Bouma BN. Inactivation of Kallikrein in human plasma. J Clin Invest 1983;71:149-58
5. Wuillemin WA, Minnema M, Meijers JC, et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role of C1-inhibitor. Blood 1995;85:1517-26
6. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985;260:1723-9
7. Landermann NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. Allergy 1962;33:330-41
8. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema. Am J Med 1963;35:37-44
9. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980;302:542-6
10. Bergamaschini L, Cicardi M, Tucci A, et al. C1 inhibitor concentrate in the therapy of hereditary angioedema. Allergy 1983;38:81-4
11. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989;83:677-82
12. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992;71:206-15
13. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334:1630-4
14. Liu D, Zhang D, Scafidi J, et al. C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 2005;105:2350-5
15. Cai S, Dole VS, Bergmeier W, et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005;174:6462-6
16. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986;25:4292-301
17. Schapira M, de Agostini A, Schifferli JA, Colman RW. Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement 1985;2:111-26
18. Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CC, et al. Proteolytic inactivation of plasma C1 inhibitor in sepsis. J Clin Invest 1989;84:443-50
19. Wagenaar-Bos IG, Hack CE. Structure and function of C1-inhibitor. Immunol Allergy Clin North Am 2006;26:615-32
20. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000;407:923-6
21. Schapira M, De Agostini A, Colman RW. C1 inhibitor: the predominant inhibitor of plasma kallikrein. Methods Enzymol 1988;163:179-85
22. Stavridi ES, O'Malley K, Lukacs CM, et al. Structural change in alpha-chymotrypsin induced by complexation with alpha 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry 1996;35:10608-15
23. De Smet BJGL, de Boer JP, Agterberg J, et al. Clearence of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 1993;81:56-61
24. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJM, et al. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C 1 -inhibitor complexes in sepsis. Blood 1988;72:1841-8
25. Wuillemin WA, Bleeker WK, Agterberg J, et al. Clearance of human factor XIa-inhibitor complexes in rats. Br J Haematol 1996;93:950-4
26. Storm D, Herz J, Trinder P, Loos M. C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem 1997;272:31043-50
27. Pizzo SV, Mast AE, Feldman SR, Salvesen G. In vivo catabolism of al-antichymotrypsin is mediated by the serpin receptor which binds al-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochem Biophys Acta 1988;967:158-62
28. Perlmutter DH, Glover GI, Rivetna M, et al. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990;87:3753-7
29. Chan JY, Burrowes CE, Habal FM, Movat HZ. The inhibition of activated factor XII (Hageman factor) by antithrombin III: effect of other plasma proteinase inhibitors. Biochem Biophys Res Commun 1977;74:150-8
30. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982;69:462-8
31. Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 1985;37:151-216
32. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1-like serine protease. J Exp Med 1992;176:1497-502
33. Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001; 194:1609-16
34. Wuillemin WA, te Velthuis H, Lubbers YT, et al. Potentiation of C1 inhibitor by glycosaminoglycanes: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997;159:1953-60
35. Wuillemin WA, Eldering E, Citarella F, et al. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem 1996;271:12913-8
36. Mauron T, Lämmle B, Wuillemin WA. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb Haemost 1998;80:82-6
37. Vogelaar EF, Brummelhuis HG, Krijnen HW Contributions to the optimal use of human blood. 3. Large-scale preparation of human c 1 esterase inhibitor concentrate for clinical use. Vox Sang 1974;26:118-27
38. Agostoni A, Bergamaschini L, Martignoni G, et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 1980;44:299-301
39. Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982;284:2-9
40. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001;161:714-8
41. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005;45:1774-84
42. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998;38:540-9
43. Poulle M, Burnouf-Radosevich M, Burnouf T Large-scale preparation of highly purified human C1-inhibitor for therapeutic use. Blood Coagul Fibrinolysis 1994;5:543-9
44. De Simoni MG, Rossi E, Storini C, et al. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol 2004;164:1857-63
45. De Simoni MG, Storini C, Barba M, et al. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab 2003;23:232-9
46. Storini C, Rossi E, Marrella V, et al. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 2005;19:10-7
47. Bergamaschini L, Gobbo G, Gatti S, et al. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin Exp Immunol 2001;126:412-20
48. Lehmann TG, Heger M, Munch S, et al. In vivo microscopy reveals that complement inhibition by C1 -esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int 2000;13(Suppl l):S547-50
49. Heijnen BH, Straatsburg IH, Padilla ND, et al. Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol 2006;143:15-23
50. Karpel-Massler G, Fleming SD, Kirschfink M, Tsokos GC. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res 2003;115:247-56
51. Padilla ND, van Vliet AK, Schools IG, et al. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 2007;142:722-33
52. Lauterbach M, Horstick G, Plum N, et al. C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia/reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion. Shock 2007;27:75-83
53. Murohara T, Guo JP, Delyani JA, Lefer AM. Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find Exp Clin Pharmacol 1995;17:499-507
54. Horstick G, Heimann A, Götze O, et al. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997;95:701-8
55. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995;91:393-402
56. Jansen PM, Eisele B, de Jong IW, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998;160:475-84
57. Fischer MB, Prodeus AP, Nicholson-Weller A, et al. Increased susceptibility to endotoxin shock in complement C3- and C4- deficient mice is corrected by C1 inhibitor replacement. J Immunol 1997;159:976-82
58. Guerrero R, Velasco F, Rodriguez M, et al. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest 1993;91:2754-60
59. Scherer RU, Giebler RM, Schmidt U, et al. The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin- induced rabbit model of hypercoagulability. Semin Thromb Hemost 1996;22:357-66
60. Liu D, Lu F, Qin G, etal. C1 inhibitor-mediated protection from sepsis. J Immunol 2007;179:3966-72
61. Salvatierra A, Velasco F, Rodriguez M, et al. C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. Am J Respir Crit Care Med 1997;155:1147-54
62. Fiane AE, Videm V, Johansen HT, et al. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immunopharmacology 1999;42:231-43
63. Hecker JM, Lorenz R, Appiah R, et al. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation 2002;73:688-94
64. Vangerow B, Hecker JM, Lorenz R, et al. C1-Inhibitor for treatment of acute vascular xenograft rejection in cynomolgus recipients of h-DAF transgenic porcine kidneys. Xenotransplantation 2001;8:266-72
65. Hack CE. Inhibitor substitution in sepsis. Intensive Care Med 1993;19:1-2
66. Hack CE, Voerman HJ, Eisele B, et al. C1 esterase inhibitor substituion in sepsis. Lancet 1992;339:378
67. Caliezi C, Zeerleder S, Redondo M, et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002;30:1722-8
68. Bauernschmitt R, Böhrer H, Hagl S. Rescue therapy with C1 -esterase inhibitor concentrate aftet emergency coronary surgery for failed PTCA. Intensive Care Med 1998;24:635-8
69. de Zwaan C, Kleine AH, Diris JH, et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002;23:1670-7
70. Thielmann M, Marggraf G, Neuhauser M, et al. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg 2006;30:285-93
71. Fattouch K, Bianco G, Speziale G, et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 2007;32:326-32
72. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006;343:1286-9
73. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-104
74. Pappalardo E, Zingale LC, Terlizzi A, et al. Mechanisms of C1-inhibitor deficiency. Immunobiology 2002;205:542-51
75. Cugno M, Nuijens J, Hack CE, et al. Plasma levels of C1 inhibitor complexes and cleaved C1 inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 1990;85:1215-20
76. Lachmann PJ, Rosen FS. The catabolism of C1 (-)-inhibitor and the pathogenesis of hereditary angio-edema. Acta Pathol Microbiol Immunol Scand Suppl 1984;284:35-9
77. Woo P, Lachmann PJL, Harrison RA, Amos N. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. Clin Exp Immunol 1985;61:1-8
78. Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol 2005;114:3-9
79. Ernst SC, Circolo A, Davis AE 3rd, et al. Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8.J Immunol 1996;157:405-10
80. Kramer J, Rosen FS, Colten HR, et al. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J Clin Invest 1993;91:1258-62
81. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007;147:11-7
82. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000;75:349-54
83. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 2003;134:1088-94
84. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119:267-74
85. Falus A, Rokita H, Walcz E, et al. Hormonal regulation of complement biosynthesis in human cell lines-II. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line. Mol Immunol 1990;27:197-201
86. Agostoni A, Cicardi M, Martignoni GC, et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 1980;65:75-9
87. Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand 1972;192:293-8
88. Frank MM, Sergent JS, Kane MA, Ailing DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972;286:808-12
89. Gelfand JA, Sherins RJ, Ailing DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295:1444-8
90. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002;36:707-9
91. Castro-Magana M, Cheruvanky T, Collipp PJ, et al. Transient adrenogenital syndrome due to exposure to danazol in uteroAm J Dis Child 1981;135:1032-4
92. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1 -inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117:904-8
93. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007;47:1028-32
94. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007;98:383-8
95. Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007;120:416-22
96. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003;29:255-8
97. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119:1497-503
98. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@ aventis.com. Transfus Apher Sci 2003;29:247-54
99. Cicardi M, Zingale LC, Zanichelli A, et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 2007;8:3173-81
100. Donaldson VH, Bissler JJ, Welch TR, et al. Antibody to C1-inhibitor in a patient receiving C1-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1-inhibitor. J Lab Clin Med 1996;128:438-43
101. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema: LevPharma, 14 March 2007. Available from: http://phx.corporate-ir.net/phoenix. zhtml?c=130944&p=irol-newsArticle& ID=1081815&highlight=
102. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema: LevPharma, 18 March 2008. Available from: http://phx.corporate-ir.net/phoenix. zhtml?c=130944&p=irol-newsArticle& ID=1119890&highlight=
103. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema. CSLBehring 26th november 2007. Available from: http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1195505474707/ prdetail.htm
104. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study. CSLBehring 18 March 2008. Available from: http://www.cslbehring.com/sl/cs/enco/ 1151517263302/news/1199979370839/prdetail.htm
105. van Doom MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005;116:876-83
106. Pharming to recieve negative negative opinion on European Authorization Application for Rhucin®: Pharming, 20 March 2008. Available from:http://www.pharming.com/index.php?act=show&pg=407
107. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005;128:2864-75
108. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-23
109. Caliezi C, Wuillemin WA, Zeerleder S, et al. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than heteditary angioedema. Pharmacol Rev 2000;52:91-112
110. De La Cadena RA, Suffredini AF, Page JD, et al. Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993;81:3313-7
111. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974;140:797-811
112. Kalter ES, van Dijk WC, Timmermann A, et al. Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 1983;148:682-91
113. Wuillemin WA, Fijnvandraat K, Derkx BH, et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995;74:1436-41
114. Herwald H, Moergelin M, Olsen A, et al. Activation of the contact-phase system on bacterial sutfaces - a clue to serious complications in infectious disease. Nat Med 1998;4:298-302
115. Pixley RA, De la Cadena RA, Page JD, et al. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992;140:897-906
116. Pixley RA, De La Cadena R, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61-8
117. Kalter ES, Daha MR, ten Cate JW et al. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:1019-27
118. Morrison DC, Kline LF. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 1977;118:362-8
119. Hack CE, Nuijens JH, Felt-Bersma RJ, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989;86:20-6
120. McCabe WR. Serum complement levels in bacteremia due to gram-negative organisms. N Engl J Med 1973;288:21-3
121. Quezado ZMA, Hoffman WD, Winkelstein JA, et al. The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure. J Exp Med 1994;179:569-78
122. Stevens JH, O'Hanley P, Shapiro JM, et al. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986;77:1818-26
123. de Boer JP Creasy AA, Chang A, et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 1993;39:59-67
124. Croner RS, Lehmann TG, Fallsehr C, et al. C1-inhibitor reduces hepatic leukocyte-endothelial interaction and the expression of VCAM-1 in LPS-induced sepsis in the rat. Mictovasc Res 2004;67:182-91
125. Zeerleder S, Caliezi C, van Mierlo G, et al. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003;10:529-35
126. Liu D, Cai S, Gu X, et al. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003;171:2594-601
127. Liu D, Gu X, Scafidi J, Davis AE 3rd. N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice. Infect Immun 2004;72:1946-55
128. Liu D, Cramer CC, Scafidi J, Davis AE 3rd. N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the cl inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A. Infect Immun 2005;73:4478-87
129. Zhang H, Li J, Barrington RA, et al. An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitot. Biochem Biophys Res Commun 2007;359:285-91
130. Krijnen PA, Meischl C, Nijmeijer R, et al. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction? Catdiovasc Hematol Disord Drug Targets 2006;6:113-23
131. Libby P, Maroko PR, Bloor CM, et al. Reduction of experimental myocardial infarction size by corticosteroid administration. J Clin Invest 1973;52:599-607
132. Hoffmeister HM, Jur M, Wendel HP, et al. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995;91:2520-7
133. McManus LM, Kolb WP, Crawford MH, et al. Complement localization in ischemic baboon myocardium. Lab Invest 1983;48:436-47
134. Rossen RD, Swain JL, Micheal LH, et al. Selective accumulation of the first component of complement and leucocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury. Circ Res 1985;57:119-30
135. Vakeva A, Morgan BP, Tikkanen I, et al. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol 1994;144:1357-68
136. Crawford MH, Grover FL, Kolb WP, et al. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 1988;78:1449-58
137. Lagrand WK, Niessen HWM, Wolbink GJ, et al. C-reactive protein and complement co-localize in the human heart after ischemia. Circulation 1997;95:97-103
138. Pinckard RN, O'Rourke RA, Crawford MH, et al. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest 1980;66:1050-6
139. Rossen RD, Swain JL, Michael LH, et al. Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury. Circ Res 1985;57:119-30
140. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol 1986;137:1945-9
141. Vakeva A, Laurila P, Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest 1992;67:608-16
142. Hugo F, Hamdoch T, Methey D, et al. Quantitative measurement of SC5b-9 and C5b-9 (m) in infarcted areas of human myocardium. Clin Exp Immunol 1990;81:132-6
143. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971;133:885-900
144. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis 1988;70:95-105
145. Yasuda M, Takeuchi K, Hiruma M, et al. The complement system in ischemic heart disease. Circulation 1990;81:156-63
146. Entman ML, Michael L, Rossen RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-37
147. Ehrengruber MU, Geiser T, Deranleau DA. Activation of human neutrophils by C3a and C5a. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett 1994;346:181-4
148. Gardinali M, Padalino P, Vesconi S, et al. Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Arch Surg 1992;127:1219-24
149. Schapira M, Despland E, Scott CF, et al. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982;69:1199-202
150. Wachtfogel YT, Kucich U, James HL, et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983;72:1672-7
151. Wachtfogel YT, Pixley RA, Kucich U, et al. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986;67:1731-7
152. Mulligan MS, Schmid E, Beck-Schimmer B, et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996;98:503-12
153. Vaporciyan AA, Mulligan MS, Warren JS, et al. Up-regulation of lung vascular ICAM-1 in rats is complement dependent. J Immunol 1995;155:1442-9
154. Simpson PJ, Todd RF 3rd, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti-CD 11b) that inhibits leukocyte adhesion. J Clin Invest 1988;81:624-9
155. Romson JL, Hook BG, Kunkel SL, et al. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;67:1016-23
156. Ito W Schafer HJ, Bhakdi S, et al. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res 1996;32:294-305
157. Grover GJ, Weiss HR. Effect of complement depletion on O2 supply and consumption in ischemic dog myocardium. Basic Res Cardiol 1987;82:57-65
158. Weisman HF, Bartow T, Leppo MK, et al. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 1990;103:64-72
159. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51
160. Fu J, Lin G, Wu Z, et al. Anti-apoptotic role for C1 inhibitor in ischemia/ reperfusion-induced myocardial cell injury. Biochem Biophys Res Commun 2006;349:504-12
161. Schreiber C, Heimisch W, Schad H, et al. C1-INH and its effect on infarct size and ventricular function in an acute pig model of infarction, cardiopulmonary bypass, and reperfusion. Thorac Cardiovasc Surg 2006;54:227-32
162. Fu J, Lin G, Zeng B, et al. Anti-ischemia/ reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity. Biochem Biophys Res Commun 2006;350:162-8
163. Cai S, Davis AE 3rd. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 2003;171:4786-91
164. MuroharaT, Margiotta J, Phillips LM, et al. Cardioprotection by liposome-conjugated sialyl Lewisx-oligosaccharide in myocardial ischaemia and reperfusion injury. Cardiovasc Res 1995;30:965-74
165. Ärzteschaft Add. Schwerwiegende Thrombenbildung nach Berinert HS. Dtarztebl 2000;97:A1016
166. Horstick G, Berg O, Heimann A, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 2001;104:3125-31
167. Hack CE, de Zwaan C, Hermens WT. Safety of C1-inhibitor for clinical use. Circulation 2002; 106:e 132; author reply e32
168. Tassani P, Kunkel R, Richter JA, et al. Effect of C1 esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J Cardiothorac Vasc Anesth 2001;15:469-73
169. Komura H, Uchiba M, Mizuochi Y, et al. Antithrombin inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by monocytes in vitro through inhibition of Egr-1 expression. J Thromb Haemost 2008;6:499-507
170. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemostas 1998;24:27-32
171. Bernard GR, Vincent JL, Laterre PR et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
172. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47
173. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78
174. Inderbitzin D, Beldi G, Avital I, et al. Local and remote ischemia-reperfusion injury is mitigated in mice overexpressing human C1 inhibitor. Eur Surg Res 2004;36:142-7
175. Akita N, Nakase H, Kaido X et al. Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 2003;52:395-400; discussion 00-1
176. Koles K, van Berkel PH, Pieper FR, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004;14:51-64